Exploring Advancements in the Treatment of Non–Small Cell Lung Cancer with EGFR Alterations : Episode 7
Second-Line Treatment of Patients With EGFR-Mutated NSCLC
Following a review of the MARIPOSA-2 trial, experts on non–small cell lung cancer discuss treatment approaches in the second line.
EP: 1.Biomarker Testing in Non–Small Cell Lung Cancer
EP: 2.NSCLC: Molecular Testing in the Metastatic Setting
EP: 3.NGS Testing Challenges and Considerations in NSCLC
EP: 4.Frontline Treatment for EGFR-Mutated Lung Cancer
EP: 5.FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
EP: 6.MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
Now Viewing
EP: 7.Second-Line Treatment of Patients With EGFR-Mutated NSCLC
EP: 8.Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations
EP: 9.NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON
EP: 10.Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC
EP: 11.Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC
Recent Videos
